New treatment approach for B-cell cancers using BTK degraders
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies
This study is testing a new medication that aims to help people with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) by targeting a protein called BTK, which can cause treatment resistance, to provide a better treatment option for everyone, no matter their specific genetic changes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10883617 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of medication that targets Bruton’s Tyrosine Kinase (BTK), a key player in B-cell malignancies like chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The approach involves creating a small molecule that can effectively degrade BTK, overcoming issues of resistance seen with current treatments. By targeting both the kinase and non-kinase functions of BTK, this therapy aims to provide a more effective treatment option for patients with these cancers. Patients may benefit from this innovative therapy, which is designed to work regardless of specific mutations in the BTK gene.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with B-cell malignancies such as chronic lymphocytic leukemia or mantle cell lymphoma.
Not a fit: Patients with B-cell malignancies who have already exhausted all treatment options or those with non-B-cell cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for patients with B-cell malignancies, potentially overcoming resistance to existing therapies.
How similar studies have performed: Previous research has shown success with BTK inhibitors, but this approach using reversible covalent degraders is novel and untested.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Wang, Jin — Baylor College of Medicine
- Study coordinator: Wang, Jin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.